Board Member
Crescent Biopharma, Inc. (CBIO)Equibles does not estimate personal net worth.
Get an email with a short summary when Crescent Biopharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get CBIO alertsJoshua Brumm is recorded as Board Member and CEO at Crescent Biopharma, Inc. (CBIO). The newest filing on record that lists Joshua Brumm as Board Member and CEO at Crescent Biopharma, Inc. (CBIO) is dated April 21, 2026. Earlier roles on record: CEO and Board Member at Dyne Therapeutics, Inc. (DYN) until March 25, 2024. Crescent Biopharma, Inc. reported in an 8-K filed July 31, 2025 that Joshua Brumm was appointed member of the board of directors. Crescent Biopharma, Inc. reported in an 8-K filed July 31, 2025 that Joshua Brumm was appointed chief executive officer. Crescent Biopharma, Inc. reported in an 8-K filed June 18, 2025 that Joshua Brumm was appointed director, effective June 13, 2025. Equibles holds 6 filed executive changes naming Joshua Brumm; each is listed under recent activity with its source filing. The proxy statement of Dyne Therapeutics, Inc. reports total compensation of $4,317,103 for Joshua Brumm in fiscal 2022, including a base salary of $610,000. Disclosed compensation is on record for 4 fiscal years. Joshua Brumm has spoken on 4 investor events across 1 company, most recently for Crescent Biopharma, Inc. on September 14, 2026. Crescent Biopharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Crescent Biopharma, Inc. includes Peter Harwin (Chairman and Board Member), Richard Scalzo (CFO), Rick Scalzo (CFO) and 7 others.
“Crescent appointed new leadership bringing experience in oncology drug development, clinical operations and building biotech companies, including Joshua Brumm as chief executive officer and member of the board of directors; Jonathan McNeill, M.D., as president and chief operating officer; Ellie Im, M.D., as chief medical officer; Rick Scalzo, MBA, as chief financial officer; Jan Pinkas, Ph.D., as chief scientific officer; Amy Reilly as chief communications officer; and Tanya Sengupta, MBA, as executive vice president, chief of strategy and operations.”
“Crescent appointed new leadership bringing experience in oncology drug development, clinical operations and building biotech companies, including Joshua Brumm as chief executive officer and member of the board of directors; Jonathan McNeill, M.D., as president and chief operating officer; Ellie Im, M.D., as chief medical officer; Rick Scalzo, MBA, as chief financial officer; Jan Pinkas, Ph.D., as chief scientific officer; Amy Reilly as chief communications officer; and Tanya Sengupta, MBA, as executive vice president, chief of strategy and operations.”
“Our own disclaimers, we have to start with a forward-looking statement, so if you have any questions on that, please see our SEC filings. Again, great to be here.”
“Just a reminder, we'll be making a forelooking statement, so please refer to our filings in that regard. For Crescent, it's been a great year.”
“I think from our perspective, ASCO is very exciting across the entire portfolio and strategy for Crescent Biopharma. I think very validating for our view on really replacing first-gen PD-1s with the new backbone therapy for IO around the biospecific class of drugs.”
“I mean, look, I think Crescent's vision is to build the world's next leading biotech oncology company. and we do that through a two-pronged approach. The first approach is on our next-gen foundational IO by-specific program, CR001.”
Start not stated–present
Last confirmed April 21, 2026
Start not stated–present
Last confirmed April 21, 2026
Start not stated–2024-03-25
Start not stated–2024-03-25
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Dyne Therapeutics, Inc. (DYN) | President and Chief Executive Officer | $610,000 | $4,317,103 |
| 2021 | Dyne Therapeutics, Inc. (DYN) | President and Chief Executive Officer | $562,000 | $4,086,611 |
| 2020 | Dyne Therapeutics, Inc. (DYN) | President and Chief Executive Officer | $482,667 | $11,868,105 |
| 2019 | Dyne Therapeutics, Inc. (DYN) | President and Chief Executive Officer | $97,212 | $277,314 |
